Isis Earns Milestone Payment From GlaxoSmithKline Related To ISIS-TTRRx

(RTTNews) - Isis Pharmaceuticals, Inc. (ISIS) announced that it has earned a $1 million milestone payment from GlaxoSmithKline (GSK.L, GSK) related to the advancement of the Phase 2/3 study of ISIS-TTRRx in patients with familial amyloid polyneuropathy. The milestone payment is the fourth of the $50 million in milestone payments Isis is eligible to earn as the Phase 2/3 study progresses.

ISIS-TTRRx is an antisense drug in development with GSK for the treatment of transthyretin amyloidosis, a severe and rare genetic disease characterized by progressive dysfunction of peripheral nerve and/or heart tissues. The Phase 2/3 study of ISIS-TTRRx is a randomized, double-blind, placebo-controlled, international study designed to support an application for marketing approval of ISIS-TTRRx in patients with familial amyloid polyneuropathy.